Vicore Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
7 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
buloxibutid (C21) / Vicore Pharma
2021-000264-29: A trial to investigate recovery from COVID-19 with C21 in adult subjects.

Not yet recruiting
3
600
RoW
Compound 21, C21, Capsule
Vicore Pharma AB, Vicore Pharma AB
COVID-19, COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
Vicore Pharma_COVID-: Vicore Pharma (Gothernburg, Sweden) garners approval to initiate Phase II clinical trial with VP01 (C21) in patients with COVID-

Not yet recruiting
2
0
Sweden
VP01 - Vicore Pharma
Vicore Pharma
 
 
NCT04533022 / 2020-000822-24: Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF

Hourglass May 2023 - May 2023 : Safety and efficacy of AIR study in idiopathic pulmonary fibrosis
Checkmark Interim data from AIR STUDY for IPF
Nov 2022 - Nov 2022: Interim data from AIR STUDY for IPF
Checkmark Interim data from AIR STUDY for IPF
Feb 2022 - Feb 2022: Interim data from AIR STUDY for IPF
Completed
2
52
Europe, RoW
C21, Buloxibutid, Compound 21
Vicore Pharma AB, Orphan Reach Ltd.
Idiopathic Pulmonary Fibrosis
03/24
03/24
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
270
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
02/27
03/27
NCT05830799: A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers

Completed
1
19
Europe
Drug Drug Interaction, Caffeine, Koffein Meda, Tolbutamide, Tolbutamide CF, Midazolam, Midazolam APL, Nintedanib, Ofev
Vicore Pharma AB
Drug Interaction
05/23
05/23
NCT05831644: A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes

Completed
1
11
Europe
C21
Vicore Pharma AB
Type2diabetes, Endothelial Dysfunction
06/23
06/23
C106 / Vicore Pharma
NCT05427253: First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects

Completed
1
80
Europe
C106 solution, Placebo
Vicore Pharma AB
Safety Issues, Tolerance, Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
06/23
06/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
buloxibutid (C21) / Vicore Pharma
2021-000264-29: A trial to investigate recovery from COVID-19 with C21 in adult subjects.

Not yet recruiting
3
600
RoW
Compound 21, C21, Capsule
Vicore Pharma AB, Vicore Pharma AB
COVID-19, COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
Vicore Pharma_COVID-: Vicore Pharma (Gothernburg, Sweden) garners approval to initiate Phase II clinical trial with VP01 (C21) in patients with COVID-

Not yet recruiting
2
0
Sweden
VP01 - Vicore Pharma
Vicore Pharma
 
 
NCT04533022 / 2020-000822-24: Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF

Hourglass May 2023 - May 2023 : Safety and efficacy of AIR study in idiopathic pulmonary fibrosis
Checkmark Interim data from AIR STUDY for IPF
Nov 2022 - Nov 2022: Interim data from AIR STUDY for IPF
Checkmark Interim data from AIR STUDY for IPF
Feb 2022 - Feb 2022: Interim data from AIR STUDY for IPF
Completed
2
52
Europe, RoW
C21, Buloxibutid, Compound 21
Vicore Pharma AB, Orphan Reach Ltd.
Idiopathic Pulmonary Fibrosis
03/24
03/24
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
270
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
02/27
03/27
NCT05830799: A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers

Completed
1
19
Europe
Drug Drug Interaction, Caffeine, Koffein Meda, Tolbutamide, Tolbutamide CF, Midazolam, Midazolam APL, Nintedanib, Ofev
Vicore Pharma AB
Drug Interaction
05/23
05/23
NCT05831644: A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes

Completed
1
11
Europe
C21
Vicore Pharma AB
Type2diabetes, Endothelial Dysfunction
06/23
06/23
C106 / Vicore Pharma
NCT05427253: First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects

Completed
1
80
Europe
C106 solution, Placebo
Vicore Pharma AB
Safety Issues, Tolerance, Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
06/23
06/23

Download Options